Skip to main content

Table 3 Patient and tumour characteristics by Consensus Molecular Subtype

From: Molecular subtyping improves prognostication of Stage 2 colorectal cancer

 

CMS1 (n = 60)

CMS2 (n = 145)

CMS3 (n = 38)

CMS4 (n = 17)

P-value*

 

(n)

%

%

%

%

Age

 < 60y

48

3.3

18.6

15.8

11.8

0.0188

 61-80y

170

48.3

53.8

60.5

52.9

 

 > 80y

90

48.3

27.6

23.7

35.3

 

Gender

 F

163

73.8

42.8

63.2

52.9

0.0009

 M

145

26.2

57.2

36.8

47.1

 

Site

 Colon

253

98.3

75.9

84.2

64.7

<  0.0001

 Rectum

55

1.7

24.1

15.8

35.3

 

Side

 Left

172

20

71

50

76.5

<  0.0001

 Right

136

80

29

50

23.5

 

Stagea

 1

53

16.7

17.2

28.9

11.8

0.01449

 2

128

55

44.8

26.3

23.5

 

 3

105

26.7

29.7

42.1

47.1

 

 4

22

1.7

8.3

2.6

17.6

 
  1. Patient and tumour characteristics by Consensus Molecular Subtype (CMS) given as percentages. N, total number of patients per group; P-value* is derived from analysis of classified tumours only and a P-value of < 0.05 is considered significant; y years, F Female, M Male; a Post-operative Tumour-Node-Metastasis staging